{"id":34271,"date":"2018-11-20T08:00:00","date_gmt":"2018-11-20T07:00:00","guid":{"rendered":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/"},"modified":"2018-11-20T08:00:00","modified_gmt":"2018-11-20T07:00:00","slug":"ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087","status":"publish","type":"press_release","link":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/","title":{"rendered":"Ipsen and 3BP announce First Patient Dosed in Phase I\/II study for first-in-class radionuclide (IPN01087)"},"content":{"rendered":"<p> <\/p>\n<p><b>Paris (France), 20 November 2018 \u2013\u00a0<\/b>Ipsen (Euronext: IPN; ADR: IPSEY) and 3BP today announced the first patient has been dosed in a Phase I\/II study for the first-in-class radionuclide\u00a0177Lu-IPN01087 (formerly known as 3BP-227). IPN01087 is a compound that targets cancer cells in patients with advanced solid tumors which express the Neurotensin Receptor Subtype 1 (NTSR1).<br \/>The key objective of the Phase I dose-escalation trial (EUDRACT Number 2017-001263-20) is to evaluate the safety and activity, as well as to identify the optimum systemically-administered dose of radiation to treat patients with any of the following solid tumors expressing NTSR1: pancreatic ductal adenocarcinoma, colorectal cancer, gastric cancer, gastrointestinal stromal tumors, Ewing sarcoma and squamous cell carcinoma of the head and neck.<br \/><b>Alexandre Lebeaut, Executive Vice President, R&amp;D and Chief Scientific Officer, Ipsen,<\/b>\u00a0said:\u00a0<em>\u201cIpsen is committed to bringing to cancer patients innovative systemic radiation therapy with targeted radiopharmaceuticals. We are pleased to report progress of the development of IPN01087 in this Phase I\/II study. Our targeted theranostic approach \u2013 which we are advancing in partnership with 3B Pharmaceuticals- provides a novel and exciting potential therapeutic solution for unmet medical needs across a number of solid tumours.\u201d<\/em><br \/><em>\u201c<\/em><em>This is a great milestone for IPN01087 and for 3B Pharmaceuticals,\u201d<\/em>\u00a0said\u00a0<b>Dr. Ulrich Reineke, Managing Director of 3BP<\/b>.\u00a0<em>\u201cWe are pleased that the compound is in clinical trials and we remain passionate about systemic radiation therapy and its potential to improve patients\u2019 lives.\u201d<\/em><\/p>\n<p><\/p>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1763],"tags":[],"class_list":["post-34271","press_release","type-press_release","status-publish","hentry","category-corporate-pressrelease","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen and 3BP announce First Patient Dosed in Phase I\/II study for first-in-class radionuclide (IPN01087) - Global<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen and 3BP announce First Patient Dosed in Phase I\/II study for first-in-class radionuclide (IPN01087) - Global\" \/>\n<meta property=\"og:url\" content=\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/\",\"name\":\"Ipsen and 3BP announce First Patient Dosed in Phase I\/II study for first-in-class radionuclide (IPN01087) - Global\",\"isPartOf\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2018-11-20T07:00:00+00:00\",\"dateModified\":\"2018-11-20T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen and 3BP announce First Patient Dosed in Phase I\/II study for first-in-class radionuclide (IPN01087)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/#website\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen and 3BP announce First Patient Dosed in Phase I\/II study for first-in-class radionuclide (IPN01087) - Global","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Ipsen and 3BP announce First Patient Dosed in Phase I\/II study for first-in-class radionuclide (IPN01087) - Global","og_url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/","og_site_name":"Global","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/","name":"Ipsen and 3BP announce First Patient Dosed in Phase I\/II study for first-in-class radionuclide (IPN01087) - Global","isPartOf":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/#primaryimage"},"image":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2018-11-20T07:00:00+00:00","dateModified":"2018-11-20T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ZmM4MTBmMGUtYTczMC00YjQzLWFjNzctMGRlNjZhYzliMjJkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-and-3bp-announce-first-patient-dosed-in-phase-i-ii-study-for-first-in-class-radionuclide-ipn01087\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/d3glparxwv1yl3.cloudfront.net\/"},{"@type":"ListItem","position":2,"name":"Ipsen and 3BP announce First Patient Dosed in Phase I\/II study for first-in-class radionuclide (IPN01087)"}]},{"@type":"WebSite","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/#website","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/","name":"Global","description":"","publisher":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/d3glparxwv1yl3.cloudfront.net\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/#organization","name":"IPSEN","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]}]}},"_links":{"self":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/press_release\/34271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/press_release\/34271\/revisions"}],"wp:attachment":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/media?parent=34271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/categories?post=34271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/tags?post=34271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}